Why Choose FloridasMMJ.com | Florida Marijuana Doctor

 Superior and Professional Customer Service

 We Only Require You To Be Seen In Person 1 x Every 210 Days

 All Orders, Adjustments & Refills Done Fast

 Customized Dosing & Treatment Management Plans 

 State Issued Medical Marijuana ID Card Assistance

 We Have Locations All Over Florida To Assist You!

The Endocannabinoid System

The endocannabinoid system is responsible for regulating balance in our body’s immune response, communication between cells, appetite and metabolism, memory, and more. In spite of the integral role it takes on, until the recent endocannabinoid system discovery, it remained an unknown part of the human body’s functions.

Named for the plant that inspired its discovery, the endocannabinoid system is important to your overall health and equilibrium, but its importance is only just becoming understood by the medical community. It is through the endocannabinoid system that the naturally occurring cannabinoids from medical marijuana interact with our bodies and trigger its beneficial effects. With the potential to greatly affect the way our bodies work, a healthy endocannabinoid system is essential and it’s key that we recognize how to maintain it.

Endocannabinoids are created in response to needs within the larger physiological system and are largely understood to be used for the body’s regulatory functions. Acting backwards on presynaptic cells, they control the volume at which communicating signals are sent. It is in this way that endocannabinoids affect duration and intensity of the wide range of physiological processes under their control.

However, it has been repeatedly noted that, while the endocannabinoid system is linked to a number of important processes and is concentrated in the brain, nervous system, and reproductive organs, it does not affect regions of the brain controlling heart and lung function. This is one of the main reasons that fatal overdoses of cannabinoids do not occur (NCI, 2016). 


Whenever there are deviations from homeostasis in the body’s functions, the endocannabinoid system is activated and begins to respond accordingly by synthesizing endocannabinoids, which act as neurotransmitters.

When the body creates endocannabinoid neurotransmitters, they are picked up by specialized cannabinoid receptors, which sit on the surface of cells. These receptors are found in a wide range of physiological regions, such as in:

  • The immune system
  • Organs and glands
  • Connective tissue
  • The brain (most significantly)

Like a key fits into a lock, endocannabinoids interact with these receptors and transmit information about changing conditions to kick-start a response, with the goal of helping the body achieve homeostasis, or equilibrium, within the body despite outside influences (Alger, 2013).

The endocannabinoid system’s receptor sites include CB1 and CB2 receptor variants, which respond differently to various cannabinoids (Pacher et al, 2006). CB1 receptors are most prevalent in the central nervous system and are linked to the following benefits:

  • Modulation of stress and anxiety
  • Increased appetite
  • Decreased nausea
  • Balance of immune system
  • Inhibition of tumors

CB2 receptors are found mostly on cells in the immune system and seem to dominate in fighting inflammation and damage to tissue. Some cells can even contain both types of receptors, each responsible for a different function says a marijuana doctor in Florida.

There are two major endocannabinoids – 2-arachidonoylglycerol (2-AG) and Anandamide (AEA).

2-AG is considered a full agonist of both CB1 and CB2 receptors. This means that it binds with, and fits well inside, both receptors to activate them to stimulate a physiological response.

Anandamide is considered a partial agonist of both receptors, because, while it binds with and activates the receptors, it doesn’t fit as well inside them and subsequently doesn’t trigger such a powerful physiological response.

Once the function that had deviated from homeostasis returns to equilibrium and the endocannabinoids are no longer needed, the third piece of the system – the metabolic enzymes – breaks down and degrades them.

Fatty acid amide hydrolase (FAAH) degrades Anandamide, and monoacylglycerol lipase (MAGL) breaks down 2-AG. By eliminating the endocannabinoids, the endocannabinoid system “turns off” the molecular signals and ends whatever physiological activity it had stimulated. Find Florida medical marijuana doctors to educate you on the endocannabinoid system and what is can do for you and your bvody.

Since discovering the endocannabinoid system and its parts, researchers have worked to further understand how the endocannabinoid system may be used therapeutically to: 

  • Decrease pain 
  • Depression
  • Fight cancer 
  • Chrons
  • Prevent neurodegenerative diseases 
  • Promote general health

Overall, research indicates that the endocannabinoid system helps ensure that the body’s immune and central nervous systems are running correctly. Finding ways to modulate the endocannabinoid system’s activity opens pathways to an amazingly disparate set of chronic diseases and disorders (Pacher and Kunos, 2013).

For example, evidence indicates that stimulation of cannabinoid receptors may aid in the deletion of old traumatic memories and provide clinical benefits in age-related diseases associated with brain inflammation (Ruehle et al, 2012) (Marchalant, et al., 2008). This list also includes difficult conditions like Parkinson’s, multiple sclerosis, and cancer.


There is also evidence that the endocannabinoid system may aid in the deletion of old memories (Ruehle et al, 2012). The extinction of  aversive memories is important to the progress of PTSD patients and in behavior conditioning for those with chronic anxiety.  By allowing patients to forget painful memories, they can reset their stress and anxiety responses to certain experiences and substitute a more positive reaction.

Appetite & Weight

Cannabis has a well-known ability to increase appetite. However, because endocannabinoids are used internally for appetite control, inverse agonists to the CB1 receptor can be used to combat obesity by shutting off the body’s desire for food (Pagotto et al, 2005). The opposite can be accomplished by stimulating appetite in those suffering from wasting syndrome and allowing them to gain weight (Kogan and Mechoulam, 2007).

Finally, endocannabinoids also regulate metabolism and help control the transfer of energy through cells, ensuring optimal use of the food we do take in.


As scientists learn more about the endocannabinoid system, they also explore the potential role the cannabis-derived cannabinoids like THC, cannabidiol (CBD), cannabinol (CBN), and more could play in supporting the system.

Science evidences a strong relationship between the endocannabinoid system and CBD. Cannabinoids, like those found in isolates and oils, mimic the behavior of endocannabinoids and interact with the cannabinoid receptors to augment the endocannabinoid system. As the cannabinoids interact with the cannabinoid receptors, they stimulate various physiological responses.

THC, the well-recognized psychoactive compound found in medical marijuana, activates receptors to elicit a chemical response. It is considered an agonist of both CB1 and CB2 receptors because it directly binds to the receptors and activates them. THC tends to favor CB1 receptors because it fits very well inside them and therefore is able to stimulate a strong physiological reaction.

When THC reacts with CB1 receptors, this is what causes the well-known “high” feeling from marijuana. THC also directly activates CB2 receptors, but is considered a partial agonist and therefore doesn’t elicit such a strong physiological response.

CBD causes chemical changes by blocking receptors. It tends to have low affinity for both CB1 and CB2 receptors, and instead acts as an indirect antagonist of agonists. This means that CBD sits imperfectly inside the receptors, not activating them but preventing other chemical messengers like THC from binding to them (Pacher, Batkai & Kunos, 2006).